公开(公告)号：US20220226298A1

公开(公告)日：2022-07-21

申请号：US17614100

申请日：2020-05-22

申请人： Kallyope, Inc.

发明人： Iyassu SEBHAT ,  Shuwen HE

IPC分类号： A61K31/4418 ,  A61K45/06 ,  C07C69/94 ,  C07D261/18 ,  C07D207/16 ,  C07D213/647 ,  C07D295/205 ,  C07D211/62 ,  C07D213/75 ,  C07D401/10 ,  C07D405/12 ,  C07F9/38 ,  C07F9/30 ,  C07F9/58 ,  A61K31/235 ,  A61K31/415 ,  A61K31/40 ,  A61K31/495 ,  A61K31/445 ,  A61K31/44 ,  A61K31/454 ,  A61K31/397 ,  A61K31/194 ,  A61K31/443 ,  A61K31/675

摘要： This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

公开(公告)号：US11358977B2

公开(公告)日：2022-06-14

申请号：US16614015

申请日：2018-05-16

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： Licong Jiang ,  Sara Sabina Hadida Ruah

IPC分类号： C07D213/75 ,  C07F9/58 ,  C07B59/00

摘要： Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. The compounds have the formula (I) wherein R is H or CH2OPO(OH)2. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

公开(公告)号：US11305268B2

公开(公告)日：2022-04-19

申请号：US16740764

申请日：2020-01-13

申请人： Dmitri Goussev ,  Denis Spasyuk

发明人： Dmitri Goussev ,  Denis Spasyuk

IPC分类号： B01J31/00 ,  B01J31/24 ,  C07F15/00 ,  C07F9/58 ,  C07B31/00 ,  B01J31/20 ,  B01J31/22 ,  C01B3/02 ,  C07C29/149 ,  C07C41/18 ,  C07C209/70 ,  B01J31/18

摘要： The present application discloses complexes useful as catalysts for organic chemical synthesis including hydrogenation and dehydrogenation of unsaturated compounds or dehydrogenation of substrates. The range of hydrogenation substrate compounds includes esters, lactones, oils and fats, resulting in alcohols, diols, and triols as reaction products. The catalysts of current application can be used to catalyze a hydrogenation reaction under solvent free conditions. The present catalysts also allow the hydrogenation to proceed without added base, and it can be used in place of the conventional reduction methods employing hydrides of the main-group elements. Furthermore, the catalysts of the present application can catalyze a dehydrogenation reaction under homogenous and/or acceptorless conditions. As such, the catalysts provided herein can be useful in substantially reducing cost and improving the environmental profile of manufacturing processes for variety of chemicals.

公开(公告)号：US11053267B2

公开(公告)日：2021-07-06

申请号：US16819377

申请日：2020-03-16

申请人： Toshiya Sagisaka ,  Hiroyuki Takahashi ,  Takashi Okada ,  Shigenobu Hirano ,  Tohru Yashiro ,  Koh Fujimura ,  Yoshihisa Naijo ,  Yoshinori Okada ,  Kazuaki Tsuji ,  Sukchan Kim ,  Keiichiroh Yutani ,  Tamotsu Horiuchi ,  Mamiko Inoue

发明人： Toshiya Sagisaka ,  Hiroyuki Takahashi ,  Takashi Okada ,  Shigenobu Hirano ,  Tohru Yashiro ,  Koh Fujimura ,  Yoshihisa Naijo ,  Yoshinori Okada ,  Kazuaki Tsuji ,  Sukchan Kim ,  Keiichiroh Yutani ,  Tamotsu Horiuchi ,  Mamiko Inoue

IPC分类号： C07D401/10 ,  C07D401/14 ,  C07F9/6558 ,  C07F9/58 ,  G02F1/1503 ,  C07F7/08 ,  C09K9/02

摘要： To provide an electrochromic compound, represented by the following general formula (I): where X1, X2, X3, X4, X5, X6, X7 and X8 are each independently a hydrogen atom or a monovalent substituent; R1 and R2 are each independently a monovalent substituent; A− and B− are each independently a monovalent anion; and Y is represented by the following general formula (II) or (III): where X9, X10, X11, X12, X13, X14, X15, X16, X17, and X18 are each independently a hydrogen atom or a monovalent substituent.

公开(公告)号：US10971689B2

公开(公告)日：2021-04-06

申请号：US15985120

申请日：2018-05-21

申请人： Merck Patent GmbH

发明人： Philipp Stoessel ,  Dominik Joosten ,  Arne Buesing

IPC分类号： H01L51/50 ,  H01L51/00 ,  C07F9/58 ,  C07C13/62 ,  C07D209/56 ,  C07D209/86 ,  C07D213/53 ,  C07D251/24 ,  C07D307/77 ,  C07D307/91 ,  C07D313/06 ,  C07D333/50 ,  C07D333/76 ,  C07D401/10 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/04 ,  C07F5/02 ,  C07F7/08 ,  C07F9/50 ,  C07F9/53 ,  C09K11/06 ,  H05B33/14 ,  C09B57/00 ,  C09B57/10 ,  C09B1/00 ,  C07C211/58 ,  C07C211/61 ,  C07D209/80 ,  C07D209/90 ,  C07D403/04 ,  C07D409/10 ,  C07D409/14 ,  C07F7/02 ,  C07F15/00

摘要： The present invention relates to compounds of the formula (1) and (2) which are suitable for use in electro¬nic devices, in particular organic electroluminescent devices.

公开(公告)号：US20200377535A1

公开(公告)日：2020-12-03

申请号：US16998426

申请日：2020-08-20

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： Corey Anderson ,  Sara Sabina Hadida Ruah ,  Julian Marian Charles Golec ,  Beili Zhang ,  Benjamin Joseph Littler ,  Ali Keshavarz-Shokri ,  Tim Edward Alcacio ,  Daniel T. Belmont

IPC分类号： C07F9/58 ,  C07F9/59 ,  C07F9/576 ,  A61K31/675 ,  A61K45/06

摘要： The invention relates to prodrug compounds of formula I: wherein R2, R3, R5, R7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.

公开(公告)号：US10689357B2

公开(公告)日：2020-06-23

申请号：US16406613

申请日：2019-05-08

申请人： Northeastern University

发明人： Michael S. Malamas ,  Alexandros Makriyannis ,  Shrouq I. Farah ,  Alexander M. Zvonok ,  Shakiru Olajire Alapafuja

IPC分类号： C07D401/04 ,  C07C331/26 ,  C07D205/04 ,  C07D213/16 ,  C07D263/34 ,  C07F9/58

摘要： Disclosed herein are compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g., inhibit) N-acylethanolamine hydrolyzing acid amidase (NAAA) and thereby treat a variety of diseases, disorders and conditions mediated by NAAA, such as a gastrointestinal motility disorder, irritable bowel syndrome, an inflammatory bowel disorder, neuroinflammation, nicotine addiction, cancer, opioid dependence, analgesia, chemotherapy-induced neuropathic pain and pain. Also disclosed herein are compositions and methods including compounds of Structural Formula I, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200147597A1

公开(公告)日：2020-05-14

申请号：US16740764

申请日：2020-01-13

申请人： Dmitri GOUSSEV ,  Denis SPASYUK

发明人： Dmitri GOUSSEV ,  Denis SPASYUK

IPC分类号： B01J31/24 ,  C07C209/70 ,  C07C41/18 ,  C07C29/149 ,  C01B3/02 ,  B01J31/22 ,  B01J31/20 ,  C07F15/00 ,  C07B31/00 ,  C07F9/58

摘要： The present application discloses complexes useful as catalysts for organic chemical synthesis including hydrogenation and dehydrogenation of unsaturated compounds or dehydrogenation of substrates. The range of hydrogenation substrate compounds includes esters, lactones, oils and fats, resulting in alcohols, diols, and triols as reaction products. The catalysts of current application can be used to catalyze a hydrogenation reaction under solvent free conditions. The present catalysts also allow the hydrogenation to proceed without added base, and it can be used in place of the conventional reduction methods employing hydrides of the main-group elements. Furthermore, the catalysts of the present application can catalyze a dehydrogenation reaction under homogenous and/or acceptorless conditions. As such, the catalysts provided herein can be useful in substantially reducing cost and improving the environmental profile of manufacturing processes for variety of chemicals.

公开(公告)号：US10583427B2

公开(公告)日：2020-03-10

申请号：US14239179

申请日：2012-08-20

申请人： Dmitri Goussev ,  Denis Spasyuk

发明人： Dmitri Goussev ,  Denis Spasyuk

IPC分类号： B01J31/00 ,  B01J31/24 ,  C07F15/00 ,  C07F9/58 ,  C07B31/00 ,  B01J31/20 ,  B01J31/22 ,  C01B3/02 ,  C07C29/149 ,  C07C41/18 ,  C07C209/70 ,  B01J31/18

摘要： The present application discloses complexes useful as catalysts for organic chemical synthesis including hydrogenation and dehydrogenation of unsaturated compounds or dehydrogenation of substrates. The range of hydrogenation substrate compounds includes esters, lactones, oils and fats, resulting in alcohols, diols, and triols as reaction products. The catalysts of current application can be used to catalyze a hydrogenation reaction under solvent free conditions. The present catalysts also allow the hydrogenation to proceed without added base, and it can be used in place of the conventional reduction methods employing hydrides of the main-group elements. Furthermore, the catalysts of the present application can catalyze a dehydrogenation reaction under homogenous and/or acceptorless conditions. As such, the catalysts provided herein can be useful in substantially reducing cost and improving the environmental profile of manufacturing processes for variety of chemicals.

公开(公告)号：US10507215B2

公开(公告)日：2019-12-17

申请号：US15974171

申请日：2018-05-08

申请人： Amygdala Neurosciences, Inc.

发明人： Carina E. Cannizzaro ,  Michael Graupe ,  Juan A. Guerrero ,  Yafan Lu ,  Robert G Strickley ,  Chandrasekar Venkataramani ,  Jeff Zablocki

IPC分类号： C07D213/64 ,  A61K31/675 ,  C07F9/58 ,  A61K31/4418

摘要： Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.